Available at research and GMP grade to intensify production of recombinant AAV rAAV viral vectors at any scale from benchtop to 2000L scale bioreactor...
Meet our Team at our booth #2 during Cell & Gene Therapy Manufacturing & Commercialization Europe, in Amsterdam, December 5-7, 2022! Don't miss our presentation on December 6 & in collaboration with DiNAMIQs!
Seamless AAV Manufacturing to the Global Gene Therapy Community : December 6, 2022 at 12:20 – 12:35 CET/CEST
Presented by Goutham K Ganjam, Head of AAV Manufacturing, DiNAMIQs, Zurich, Switzerland
DiNAMIQs AAV manufacturing platform is based on triple plasmid transfection of suspension HEK293 with FectoVIR®-AAV in shake flasks, stir tank bioreactors (2L, 4L and 50L) and purified by chromatography. Aligned with GMP regulations, we provide your high-quality vectors and minimal changes moving forward to your clinical applications. With FectoVIR®-AAV based transfection we achieve 35-40% of final enriched AAV full fraction.
Development of a novel helper plasmid: one step closer to the next generation rAAV vectors
Eric Mauro, Jonathan Havard, Sylvain Julien, Laure Robert, Carine Morel, Patrick Erbacher
To broaden the use of rAAVs to treat a wider spectrum of monogenic diseas for small and larger indications, the aim is to improve specificity, safety and patient affordability. For this, it is key to improve rAAV production yields to decrease manufacturing costs, and improve functional titers to administer lower and safer doses. To this end, our research is focused on developing novel technologies to ensure manufacturing of high yielding rAAV using transient transfection, as well as enhancing features of the rAAV vectors that act on the overall size of packaged material and specificity of delivery.
Here we present our state-of-the art approach to designing new helper plasmids (phelpers) with the aim of improving both the infectiosity (TU/mL) and the quality (full/empty ratio) of the viral particle obtained from suspensions cultures. We took the opportunity to exploit our proprietary DNA assembly method technology, to rationally explore the synergies of multiple genetic features modularly assembled in synthetic plasmids. Comparison of the biological activity of several versions of rationally designed pHelpers led us to identify the optimal configuration able to outperform existing helper plasmids in every tested bioproduction conditions. Our ability to assemble tailor designed DNA plasmids and our expertise in developing scalable transfection solutions for rAAV manufacturing gives us potential to improve both productivity and specificity of gene therapy products.